摘要
目的 探讨晚期肺癌患者血栓预防的临床价值.方法 选取晚期肺癌患者80 例,随机均分为观察组(n=41)和对照组(n=39),对照组给予常规治疗,观察组在常规治疗的基础上加用低分子肝素钙治疗,检测2 组治疗前后血小板计数(PLT)、D-二聚体(D-D)、纤维蛋白原(FIB)、凝血酶原时间(PT)和部分活化凝血活酶时间(APTT),同时观察深静脉血栓、肺栓塞的发生情况.结果 治疗后,观察组PLT、D-D和FIB水平分别为(301.10±22.30)×109/L、(271.10±71.02)mg/L 和(3.60±0.32)g/L,均低于对照组的(388.18±26.61)×109/L、(410.02±77.40)mg/L、(4.01±0.40)g/L(t=15.894,P<0.001;t=8.371,P<0.001;t=5.075,P<0.001);观察组PT和APTT水平分别为(11.28±1.01)、(25.03±1.01)s,均高于对照组的(10.28±1.05)、(24.17±0.92)s(t=4.341,P<0.001;t=3.975,P<0.001);观察组深静脉血栓发生率为 4.88%,低于对照组的 23.08%(χ2=5.582,P=0.018).结论 低分子肝素钙能有效预防晚期肺癌患者血栓的发生,值得临床使用.
Abstract
Objective To explore the clinical value of thromboprophylactic therapy for advanced lung cancer.Methods Eighty patients with advanced lung cancer were selected,the patients were randomly divided into the observation group(n=41)and the control group(n=39)by random number table method,the control group was given routine treat-ment,while the observation group was treated with low molecular weight heparin calcium on the basis of routine treatment,the platelet count(PLT),D-dimer(D-D),fibrinogen(FIB),prothrombin time(PT)and partially activated thromboplas-tin time(APTT)were measured before and after treatment in both groups,the occurrence of deep venous thrombosis and pulmonary embolism was also observed.Results Compared to the control group[(301.10±22.30)×109/L,(271.10±71.02)mg/L,(3.60±0.32)g/L],PLT,D-D and FIB levels after treatment in the observation group[(301.10±22.30)×109/L、(271.10±71.02)mg/L and(3.60±0.32)g/L]were significantly lower(t=15.894,P<0.001;t=8.371,P<0.001;t=5.075,P<0.001);Compared to the control group[(10.28±1.05),(24.17±0.92)s],PT and APTT after treatment in the observation group[(11.28±1.01),(25.03±3.01)s]were significantly higher(t=4.341,P<0.001;t=3.975,P<0.001);Compared to the control group(23.08%),the incidence of deep venous thrombosis in the observation group(4.88%)was lower(χ2=5.582,P=0.018).Conclusion Low molecular weight heparin calcium can effectively prevent the occurrence of thrombosis in patients with advanced lung cancer,which is worthy of clinical use.
维普
万方数据